FULCRUM THERAPEUTICS, INC.

Company

Fulcrum Therapeutics, Inc.

Filed

March 10, 2022

Accession Number

0000902664-22-002084

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →